# A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)

> **NCT02365441** · PHASE2 · UNKNOWN · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 78 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumour

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** imatinib

## Key facts

- **NCT ID:** NCT02365441
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06-30
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-07-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365441, "A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02365441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*